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Abstract
Background: Uncontrolled proliferation and increased motility are hallmarks of neoplastic cells, therefore markers of
proliferation and motility may be valuable in assessing tumor progression and prognosis. MCM2 is a member of the
minichromosome maintenance (MCM) protein family. It plays critical roles in the initiation of DNA replication and in
replication fork movement, and is intimately related to cell proliferation. Ki-67 is a proliferation antigen that is expressed
during all but G0 phases of the cell cycle. Gelsolin is an actin-binding protein that regulates the integrity of the actin
cytoskeletal structure and facilitates cell motility. In this study, we assessed the prognostic significance of MCM2 and Ki-
67, two markers of proliferation, and gelsolin, a marker of motility, in non-small cell lung cancer (NSCLC).
Methods:  128 patients with pathologically confirmed, resectable NSCLC (stage I-IIIA) were included.
Immunohistochemistry was utilized to measure the expressions of these markers in formalin-fixed, paraffin-embedded
tumor tissues. Staining and scoring of MCM2, Ki-67 and gelsolin was independently performed. Analyses were performed
to evaluate the prognostic significance of single expression of each marker, as well as the prognostic significance of
composite expressions of MCM2 and gelsolin. Cox regression and Kaplan-Meier survival analysis were used for statistical
analysis.
Results: Of the three markers, higher levels of gelsolin were significantly associated with an increased risk of death
(adjusted RR = 1.89, 95% CI = 1.17–3.05, p = 0.01), and higher levels of MCM2 were associated with a non-significant
increased risk of death (adjusted RR = 1.36, 95% CI = 0.84–2.20, p = 0.22). Combined, adjusted analyses revealed a
significantly poor prognostic effect for higher expression of MCM2 and gelsolin compared to low expression of both
biomarkers (RR = 2.32, 95% CI = 1.21–4.45, p = 0.01). Ki-67 did not display apparent prognostic effect in this study
sample.
Conclusion: The results suggest that higher tumor proliferation and motility may be important in the prognosis of
NSCLC, and composite application of biomarkers might be of greater value than single marker application in assessing
tumor prognosis.
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Background
Abnormal cell proliferation, which results from deregula-
tion of the cell cycle, is fundamental in tumorigenesis. The
integrated mechanisms that regulate the accurate replica-
tion of DNA and correct division of cells are thus pivotal
in the neoplastic process [1,2]. Regulation of the cell cycle
is complex and involves a wide variety of genes and pro-
teins, among which the minichromosome maintenance
(MCM) nuclear proteins are essential replication initia-
tion factors. The MCM protein family consists of six major
isoforms (MCM2-7), which have similar biochemical
functions [3] and are equally important for continuous
chromosome replication after the activation of early ori-
gins of DNA replication [4]. During the cell cycle, the
MCM proteins form a hexameric complex, which is a key
component of the prereplication complex that assembles
at replication origins during early G1 phase [3,5]. MCM
proteins restrict DNA synthesis to only once per cell cycle
[3,4,6], and regulate DNA elongation [4]. These functions
of MCM proteins imply that they are correlated with cell
proliferation, which has been consistently supported by
experimental evidence. For example, the onset of DNA
synthesis was inhibited if anti-MCM2 antibody was
injected into cells during G1 [6], and depletion of MCMs
after initiation irreversibly blocked the progression of rep-
lication forks [4]. Moreover, MCM2 expression in devel-
oping  Drosophila  embryos followed a pattern
corresponding to the fast dividing cells, and inactivation
of MCM2 inhibited cell proliferation [7]. Cellular expres-
sion of MCMs was constitutively high in proliferating cells
but low or undetectable in quiescent cells [3,8,9].
Ki-67, another important cell proliferative biomarker, is a
nuclear protein containing phosphorylation sites for a
variety of kinases, putative nuclear targeting sequences,
and a forkhead-associated domain, similar to those of
cell-cycle-regulating proteins [10-12]. During mitosis,
phosphorylation and dephosphorylation of Ki-67 occur
at the breakdown and the reorganization of the nucleus,
two hallmark occasions of the cell cycle. These posttrans-
lational modifications are accompanied by the redistribu-
tion of Ki-67 from the interior of the nucleus to the
periphery of the condensed chromosomes and vice versa
[12,13]. Although recognized as a cell cycle regulating
protein, the specific functions of Ki-67 remain elusive,
mainly due to its lack of homology with other proteins
[13]. Some proposed functions of Ki-67 include organiza-
tion and maintenance of the architecture of DNA, and
synthesis of ribosomes during mitosis [14,15]. Since Ki-
67 is expressed during all phases of the cell cycle except
G0, cellular expression of Ki-67 has provided a measure of
tumor proliferation [16,17]. The prognostic value of Ki-67
has been reported in various tumors, including cancers of
breast, soft tissue, lung, cervix, prostate, and brain [17-
21].
Gelsolin is the most potent actin binding and severing
protein identified to date which is widely expressed in
mammalian tissues [22,23]. It regulates the integrity and
dynamics of actin cytoskeleton and maintains the proper
cellular morphological structure and motility through
severing, capping and nucleating actin filaments [23-25].
Knockout animal models have clearly demonstrated the
critical role of gelsolin in facilitating cell motility [26-30].
An inverse association between gelsolin expression and
patient survival time has been observed in lung cancer and
breast cancer [31-33], suggesting cellular motility medi-
ated through gelsolin expression plays an important role
in the progression and prognosis of malignant tumors.
Although MCM2, Ki-67, two markers of cell proliferation,
and gelsolin, marker of cell motility, have been previously
studied, no study has been conducted assessing the poten-
tial combined prognostic effect of these markers in non-
small cell lung cancer (NSCLC).
Methods
Study population
Two hundred and twenty-one patients who were patho-
logically diagnosed with NSCLC and received surgical
treatment at the Roswell Park Cancer Institute (RPCI)
from 1995 to 1999 were included in the current study.
These patients were identified and selected based on the
following criteria: 1) no previous history of cancer; 2) no
other primary cancers diagnosed within one month of the
current diagnosis; 3) initial surgery for NSCLC at RPCI; 4)
pathology report of complete removal of gross tumor at
surgery; and 5) minimum survival of one month after sur-
gery. After examination of patient follow-up data and
tumor immunostaining, 53 patients were excluded due to
inadequate tumor specimen or poor staining, and 40 were
excluded due to causes of death not related to lung cancer,
leaving a total of 128 patients in the current analysis. The
pathological stage of these patients included 75 stage I, 31
stage II, and 22 stage IIIA, and histological classification
included 77 adenocarcinomas, 39 squamous cell carcino-
mas, 5 large cell tumors, and 7 tumors with mixed histo-
logical differentiation. The majority of tumors were
poorly differentiated (60.2%), and the remainder was
well and moderately differentiated (39.8%). This study
was approved by the Institutional Review Board at RPCI.
Tumor and patient data
Patient clinicopathological data were retrieved from med-
ical records. These data included sex, age, race, lifetime
smoking history, family history of lung cancer, date of
diagnosis, date of surgery, adjuvant chemotherapy, path-
ological TNM stage of tumor, histology, grade, perform-
ance status, weight loss, and date of last follow-up. Patient
performance status was scored according to the Zubrod
Performance Scale [34]. Weight loss was defined as moreBMC Cancer 2006, 6:203 http://www.biomedcentral.com/1471-2407/6/203
Page 3 of 10
(page number not for citation purposes)
than 5% of weight loss within three months prior to the
diagnosis. The date of last follow-up was the date of death
for deceased patients, and the last date of contact for living
patients by the Department of Medical Record at RPCI.
Detection and scoring methods
Tissue specimens obtained from diagnostic or surgical
procedures were fixed in neutral buffered formalin (10%
vol/vol formalin in water; pH = 7.4), and embedded in
paraffin wax. Consecutive 5-μm thick tumor sections were
cut and mounted on charged glass slides (Superfrost Plus;
Fisher Scientific, Rochester, NY). Sections were warmed at
60–70°C for 20 minutes, and then were deparaffinized in
xylene, and rehydrated in 100% and 95% ethanol. Anti-
gen retrieval was performed for Ki-67 and gelsolin stain-
ing. Sections to be treated with antibodies against Ki-67 or
gelsolin were microwaved twice for 10 minutes in citrate
buffer, followed by cooling to room temperature for 20
minutes. Our previous study showed good immunohisto-
chemical staining for anti-MCM2 antibody without anti-
gen retrieval [9]. An affinity-purified rabbit antibody
against the N-terminal region of MCM2 was used for
MCM2 staining [9]. Since the epitope recognized by anti-
Ki-67 antibody is usually destroyed during formalin fixa-
tion and paraffin embedding [35], we utilized MIB-1
mouse monoclonal antibody to detect Ki-67 antigen
(Immunotech Inc., Westbrook, ME). MIB-1 antibody was
developed using a recombinant partial structure of the Ki-
67 antigen as immunogen, and it is widely used as a Ki-67
equivalent monoclonal antibody [35]. It can detect Ki-67
antigen in formalin-fixed, paraffin-embedded tissues
through antigen retrieval, and the immunostaining pat-
tern in fresh frozen tissue is identical to that of anti-Ki-67
antibody [36]. The MCM2 antibody, generated as
described by Todorov et al. [9], and MIB-1 antibody were
incubated for 60 and 30 minutes at room temperature
and used at dilutions of 1:500 and 1:100, respectively, for
optimal staining effect. The avidin-biotin detection
method was used on a Ventana Automated System (Ven-
tana Medical Systems, Tucson, AZ). An irrelevant rabbit
antiserum was used as a negative control. The percentage
of nuclei stained for both antibodies in cancer cells was
evaluated by two investigators (D.T. and J.S.J.B.).
For gelsolin immunoassay, the primary anti-gelsolin
monoclonal antibody GS-2C4 (Sigma Chemical Co., St.
Louis, MO) was titrated at the optimal concentration of
1:1000 in phosphate buffered saline. The antibody was
manually added to each section and incubated at 42°C for
32 minutes. All other staining procedures were performed
by the Ventana 320 Automated Slide Staining System
(Ventana Medical Systems, Tucson, AZ), using the ABC
(avidin-biotin-conjugate) immunoperoxidase protocol
with goat anti-mouse (peroxidase-conjugated) as second-
ary antibody. In order to assess the performance of the
overall staining process, normal lung tissue sections from
clinical biopsies were used as external positive and nega-
tive staining controls in each run. Negative controls were
exposed to all steps in the Ventana System except the pri-
mary antibody. Stained slides were evaluated and scored
simultaneously by two research investigators (D. F. T. and
J. Y.) under a multi-head light microscope. The percentage
of tumor cells was determined at four staining intensities
(0, 1+, 2+, or 3+). Pulmonary macrophages (3+), fibrob-
lasts (2+), and normal lung epithelial cells (1+ to 2+)
adjacent to tumor cells (if available) were used as scoring
references [31,37]. The percentage of tumor cells at four
staining intensities was counted. To assess the inter-
observer variability of scoring, approximately half of the
cases (n = 56) were randomly selected and reviewed by
two pathologists (D. F. T. and J. G.) independently, which
yielded an inter-observer agreement of 81%.
Based on the current literature and our experiences, the
phenotypic expression features of MCM2, Ki-67, and gel-
solin warranted different scoring systems for these three
markers. MCM2 and Ki-67 expression was defined as low
if less than 25% of tumor cells showed staining in nuclei
in a tumor section. This definition was used according to
the commonly used cutoff values ranging from 20–40%
in non-small cell lung cancer and other human cancers in
the current literature [38-41] and also based on the exam-
ination of our staining data. For gelsolin expression, an
index was calculated to account for non-uniform expres-
sion in terms of staining intensity and number of tumor
cells at each intensity. The index was calculated by multi-
plying the percentage of tumor cells by the corresponding
staining intensity, as described previously [33]. Since the
index distribution was skewed, the median (score = 40)
rather than the mean (score = 63) value was used as the
cut-point for the dichotomization of gelsolin expression
(low if index ≤40, and high if index >40).
Statistical methods
The Student's t-test and chi-square test were used to exam-
ine the association between the expression of MCM2, Ki-
67 and gelsolin and patient clinicopathological character-
istics. For smoking status, stage, and grade, which were
measured as ordinal variables, we utilized Kendall's tau-b
test for the chi-square analysis to take into account the
ordinal measurement. Exact tests were used when cell fre-
quencies were less than 10. The examination of propor-
tional hazards showed that the hazards were proportional
for MCM2 and gelsolin over time, but non-proportional
for Ki-67, thus we used Cox proportional hazards regres-
sion to compute the relative risk (RR) of death for MCM2
and gelsolin, and used the time-dependent Cox regression
to evaluate the prognostic value of Ki-67 [42]. Kaplan-
Meier survival analysis was used to generate survival
curves. The log rank test was utilized to examine the dif-BMC Cancer 2006, 6:203 http://www.biomedcentral.com/1471-2407/6/203
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ference of the accumulated survival function for MCM2
and gelsolin, and Breslow test was used to test the differ-
ence of survival function for Ki-67, which takes into
account the number of cases in risk at each time point
over the follow-up period. Age and factors that demon-
strated a significant prognostic effect in the univariate
model (stage, adjuvant chemotherapy, family history of
lung cancer, and smoking history) were adjusted for RR
estimation in the multivariate Cox regression model. All
analytic procedures were performed using SPSS statistical
software version 13.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics are summarized in Table 1. The
majority of patients were Caucasian (93.8%). There were
more male (54.7%) than female patients (45.3%). The
majority of patients were former smokers (50%) or cur-
rent smokers (41%). About one third of patients had a
positive family history of lung cancer. The mean and
median survival time among deceased patients was 29.4
and 26.5 months, respectively (range: 1.5–84.7 months).
The mean and median follow-up time for living patients
was 68.3 and 67.0 months, respectively (range: 42.7–
128.4 months). Forty-nine patients (38.3%) were alive at
the last contact on December 30th, 2003.
The phenotypic expressions of MCM2, Ki-67, and gelsolin
are shown in Figure 1, which depicts examples of negative
expression (C and E), low expression (A and F), and high
expression (B, D and G), respectively. Examination of
MCM2, Ki-67, and gelsolin expression showed that
61.7%, 78.1% and 32.8% of tumors exhibited high
expression of these three proteins, respectively (Table 1).
Patient characteristics stratified by levels of MCM2, Ki-67
and gelsolin expression are shown in Table 2. None of the
clinicopathological factors showed a significant associa-
tion with Ki-67 expression. For MCM2, high expression
was associated with sex (male patients: 64.6% vs. 38.8%),
histology (squamous carcinomas: 45.6% vs. 6.1%), and
grade (poorly differentiated tumors: 68.4% vs. 46.9%).
For gelsolin, high expression was associated with sex
(female patients: 66.7% vs. 51.2%), and histology (squa-
mous carcinomas: 38.1% vs. 26.7%).
Univariate analysis of the prognostic significance of
MCM2, Ki-67, and gelsolin showed higher levels of gelso-
lin were significantly associated with an elevated risk of
death compared to low levels of gelsolin (RR = 1.89, 95%
CI = 1.20–2.98, p = 0.006), and higher levels of MCM2
were associated with a non-significant increased risk of
death compared to low levels of MCM2 (RR = 1.51, 95%
CI = 0.94–2.41, p = 0.09). Ki-67 expression did not dis-
play apparent prognostic effect in this study sample (RR =
0.70, 95% CI = 0.27–1.86, p = 0.47). After controlling for
age, stage, adjuvant chemotherapy, family history of lung
Table 1: Characteristics of 128 Non-small Cell Lung Cancer 
Patients, RPCI, 1995–1999
Characteristics N = 128 (%)
Sex
Male 70 (54.7%)
Female 58 (45.3%)
Race
Caucasians 120 (93.8%)
Non-Caucasians 8 (6.2%)
Age
Mean (SD) 64.2 (10.7)
Smoking status
Never 11 (8.6%)
Former 64 (50.0%)
Current 53 (41.4%)
Pack-years of smoking(a)
Mean (SD) 51.4 (27.0)
Family history of lung cancer
No 87 (68.0%)
Yes 41 (32.0%)
Zubrod Performance status
Without symptom 87 (68.0%)
With symptom 41 (32.0%)
Weight loss(b)
No 110 (85.9%)
Yes 18 (14.1%)
Vital status
Alive 49 (38.3%)
Dead 79 (61.7%)
Pathologic TNM stage
I 75 (58.6%)
II 31 (24.2%)
IIIA 22 (17.2%)
Histology
Adenocarcinoma 77 (60.2%)
Squamous 39 (30.5%)
Large cell 5 (3.9%)
Others 7 (5.5%)
Grade
Well differentiation 3 (2.3%)
Moderate differentiation 48 (37.5%)
Poor differentiation 77 (60.2%)
Receiving adjuvant chemotherapy
No 109 (85.2%)
Yes 19 (14.8%)
MCM2
Low 49 (38.3%)
High 79 (61.7%)
Ki-67
Low 28 (21.9%)
High 100 (78.1%)
Gelsolin level
Low 86 (67.2%)
High 42 (32.8%)
(a). Pack-years of smoking: packs of cigarette smoked per day 
multiplied by years of smoking;
(b). Weight loss: ≥ 5% of total weight loss within 3 months prior to 
diagnosis.BMC Cancer 2006, 6:203 http://www.biomedcentral.com/1471-2407/6/203
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cancer, and smoking history, the significant association
remained between high levels of gelsolin and elevated risk
of death (RR = 1.89, 95% CI = 1.17–3.05, p = 0.01). The
prognostic effect of MCM2 was attenuated after control-
ling for confounders (RR = 1.36, 95% CI = 0.84–2.20, p =
0.22) (Table 3).
Composite analysis of MCM2 and gelsolin expression
revealed that higher expression in MCM2 and gelsolin was
significantly associated with higher risk of death com-
pared to low expression in both biomarkers (adjusted RR
= 2.32, 95% CI = 1.21–4.45, p = 0.01) (Table 3, Figure 2).
Since the hazards function was not proportional for Ki-67,
we did not analyze the combined prognostic effect of Ki-
67 with MCM2 and gelsolin in the Cox Proportional Haz-
ards Regression. Survival curves generated from Kaplan-
Meier survival analysis are illustrated in Figure 2. The
curves confirmed the results from Cox regression that
patients with higher levels of MCM2 and gelsolin experi-
enced shorter survival time than patients with low levels
of MCM2 and gelsolin.
Discussion
The relative balance between cell growth and cell death is
altered in cancers, with the balance tipped towards uncon-
trolled proliferative capacity in cancer cells [1,43]. In addi-
tion, some cancer cells acquire a markedly enhanced
capacity to move, thereby predisposing them to invasion
and dissemination [44,45]. Findings from the present
study showed that tumors exhibiting higher levels of
expression in MCM2, a marker of proliferation, and gelso-
lin, a marker of motility, conferred a higher risk of death
in NSCLC.
MCM proteins are essential replication initiation factors
that ensure the accurate replication of DNA in the cell
cycle. Through accurate binding to chromatin during G1
phase and detaching from chromatin during S phase,
MCM proteins restrict DNA synthesis to only once per cell
cycle [3,4,6]. Only licensed origins containing MCM pro-
teins can initiate a pair of replication forks, and once ini-
tiation occurs at an origin, the bound MCM proteins are
displaced so that the origin cannot fire again [46]. MCM
proteins may also function as the helicase that unwinds
DNA ahead of each replication fork [47]. Evidence from
different organisms and cells indicates that both perma-
nently arrested cells and those in G0 phase have lost
expression of MCM proteins and are functionally unli-
censed [48-50]. The replication initiation function of
MCM proteins in cell cycle implies that they may be valu-
able markers for proliferation and prognosis in human
cancers. Todorov et al. studied MCM2 expression in nor-
mal and tumor human tissues and found MCM2 was
expressed significantly different in specimens examined,
with expression of 97% in tumors but only 27% in nor-
mal tissues. Furthermore, the expression level in normal
tissues was lower than in tumor tissues, indicating that
MCM2 reflects cell proliferation [9]. Dudderidge et al.
studied MCM2, geminin, and Ki-67 in renal cell carci-
noma and found that MCM2 expression increased dra-
matically with increasing grade [41]. Hashimoto et al.
investigated MCM2 and Ki-67 expression in lung adeno-
carcinomas and found that the co-expression of MCM2
and Ki-67 at higher levels were significantly associated
with poorer survival [39]. The prognostic value of MCM2
was also reported in bladder cancer and oligodendrogli-
oma [40,51].
Ki-67 is expressed in all stages of the cell cycle except G0
phase, making it a valuable measurement for cell prolifer-
ation [12]. In a number of cancers, elevated Ki-67 expres-
sion has been found associated with higher aggressiveness
and invasiveness [52-54]. The prognostic value of Ki-67
has been observed in cancers of breast, prostate, cervix,
and soft tissue [21]. In a comprehensive review, Pugsley et
al. noted that higher Ki-67 index was significantly associ-
ated with poorer survival in NSCLC in the majority of uni-
variate analyses and in approximately half of the
multivariate analyses [38]. In our study, we did not
observe the prognostic effect of Ki-67 expression in both
Representative images showing immunostaining of prolifera- tion and motility markers (MCM2, Ki-67 and gelsolin) in  NSCLC Figure 1
Representative images showing immunostaining of prolifera-
tion and motility markers (MCM2, Ki-67 and gelsolin) in 
NSCLC. A: low MCM2; B: high MCM2; C: negative Ki-67 
(note: a few active lymphocytes are positive); D: high Ki-67; 
E: negative gelsolin; F: low gelsolin; G: high gelsolin. Magnifica-
tion ×400 in D, E, F, and G; ×200 in A, B, and C.
AB
CD
EF
G
AB
CD
EF
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the univariate and multivariate analysis, which may be
partially due to the limited sample size. The small sample
size also prevented additional examination of the prog-
nostic value of MCM2, Ki-67 and gelsolin in subgroup
patients. As Pugsley et al. pointed out, factors such as
patient heterogeneity, retrospective nature of study
design, quantification of immunohistochemistry, and
cutoff value may contribute to the inconsistent findings
for the prognostic value of Ki-67 NSCLC in the literature
[38].
In addition to proliferation, elevated motility is essential
for tumor cells to invade and disseminate [44,45,55,56].
Highly metastatic cells typically exhibit enhanced loco-
motion capacity compared to less metastatic cells
[44,45,57,58]. Various studies have consistently shown
that higher levels of motility are associated with higher
Table 2: Association between MCM2, Ki-67, and Gelsolin and Clinicopathological Characteristics in 128 Patients with NSCLC, RPCI, 
1995–1999
Clinicopathological Characteristics Low MCM2 
(n = 49)
High MCM2 
(n = 79)
Low Ki-67 (n 
= 28)
High Ki-67 (n 
= 100)
Low GSN (n = 86) High GSN (n = 42)
Gender
Male 19 (38.8%) 51 (64.6%)** 13 (46.4%) 57 (57.0%) 42 (48.8%) 14 (33.3%)*
Female 30 (61.2%) 28 (35.4%) 15 (53.6%) 43 (43.0%) 44 (51.2%) 28 (66.7%)
Race
Caucasians 47 (95.9%) 73 (92.4%) 26 (92.9%) 94 (94.0%) 83 (96.5%) 37 (88.1%)
Non-Caucasians 2 (4.1%) 6 (7.6%) 2 (7.1%) 6 (6.0%) 3 (3.5%) 5 (11.9%)
Mean age (SD) Smoking status 64.7 (9.2) 63.9 (11.6) 63.0 (10.9) 64.6 (10.7) 64.8 (9.6) 63.2 (12.8)
Current 18 (36.7%) 35 (44.3%) 11 (39.3%) 42 (42.0%) 34 (39.5%) 19 (45.2%)
Former 27 (55.1%) 37 (46.8%) 14 (50.0%) 50 (50.0%) 43 (50.0%) 21 (50.0%)
Never 4 (8.2%) 7 (8.9%) 3 (10.7%) 8 (8.0%) 9 (10.5%) 2 (4.8%)
Mean pack-years (SD)(a) 47.9 (30.2) 46.4 (29.4) 45.6 (36.4) 47.4 (27.6) 44.6 (28.8) 51.9 (31.0)
Family history
No 35 (71.4%) 52 (65.8%) 23 (82.1%) 64 (64.0%) 58 (67.4%) 29 (69.0%)
Yes 14 (28.6%) 27 (34.2%) 5 (17.9%) 36 (36.0%) 28 (32.6%) 13 (31.0%)
Pathology Stage
I 30 (61.2%) 45 (57.0%) 16 (57.1%) 59 (59.0%) 52 (60.5%) 23 (54.8%)
II 15 (30.6%) 16 (20.2%) 8 (28.6%) 23 (23.0%) 22 (25.6%) 9 (21.4%)
IIIA 4 (8.2%) 18 (22.8%) 4 (14.3%) 18 (18.0%) 12 (14.0%) 10 (23.8%)
Tumor size
≤3 cm 22 (45.8%) 27 (34.2%) 12 (42.9%) 37 (37.4%) 35 (41.2%) 14 (33.3%)
>3 cm 26 (54.2%) 52 (65.8%) 16 (57.1%) 62 (62.6%) 50 (58.8%) 28 (66.7%)
Lymph node status
Negative 34 (70.8%) 47 (59.5%) 18 (64.3%) 63 (63.6%) 58 (68.2%) 23 (54.8%)
Positive 14 (29.2%) 32 (40.5%) 10 (35.7%) 36 (36.4%) 27 (31.8%) 19 (45.2%)
Histology
Adenocarcinoma 41 (83.7%) 36 (45.6%)** 20 (71.4%) 57 (57.0%) 56 (65.1%) 21 (50.0%)*
Squamous 3 (6.1%) 36 (45.6%) 6 (21.4%) 33 (33.0%) 23 (26.7%) 16 (38.1%)
Large cell 2 (4.1%) 3 (3.8%) 1 (3.6%) 4 (4.0%) 5 (5.8%) 0 (0.0%)
Others 3 (6.1%) 4 (5.1%) 1 (3.6%) 6 (6.0%) 2 (2.3%) 5 (11.9%)
Grade
Well differentiation 1 (2.0%) 2 (2.5%)* 2 (7.1%) 1(1.0%) 1(1.1%) 2(4.8%)
Mod. differentiation 25 (51.1%) 23 (29.1%) 13 (46.4%) 35 (35.0%) 33 (38.4%) 15 (35.7%)
Poor differentiation 23 (46.9%) 54 (68.4%) 13 (46.4%) 64 (64.0%) 52 (60.5%) 25 (59.5%)
Performance Status
Without symptom 32 (65.3%) 55 (69.6%) 21 (75.0%) 66 (66.0%) 61 (70.9%) 26 (61.9%)
With symptom 17 (34.7%) 24 (30.4%) 7 (25.0%) 34 (34.0%) 25 (29.1%) 16 (38.1%)
Weight loss(b)
No 43 (87.8%) 67 (84.8%) 24 (85.7%) 86 (86.0%) 76 (88.4%) 34 (81.0%)
Yes 6 (12.2%) 12 (15.2%) 4 (14.3%) 14 (14.0%) 10 (11.6%) 8 (19.0%)
Mean survival in month (SD) 49.8 (28.0) 40.8 (25.7) 50.0 (31.3) 42.7 (25.4) 48.0 (26.6) 36.7 (26.1)*
(a). Pack-years of smoking: packs of cigarette smoked per day multiplied by years of smoking;
(b). Weight loss: ≥ 5% of total weight loss within 3 months prior to diagnosis.
* p ≤ 0.05; **: p ≤ 0.01BMC Cancer 2006, 6:203 http://www.biomedcentral.com/1471-2407/6/203
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rates of tumor metastasis or shorter survival time [31-
33,59-62]. The motility facilitating function of gelsolin
has been widely observed in animal models [26-29]. We
and others have showed that higher levels of gelsolin are
associated with poorer survival in breast and lung cancer
[31-33]. Some studies failed to find a prognostic signifi-
cance for gelsolin. However, these studies are generally
subject to small sample size or inadequate follow-up time
[37,63-65]. As a generalization, the gelsolin content of the
cells in most cancers is found to be down-regulated
[37,64-66], but in a number of studies, researchers found
that high gelsolin expression is inversely associated with
survival time [31-33]. For example, we found that tumors
with high and heterogeneous expression of gelsolin con-
ferred the highest risk of death from NSCLC in patients
with this disease [33]. Shieh et al. found that the most
potent predictor of poor prognosis was high focal gelsolin
expression [31]. Increased expression of gelsolin may
facilitate a subset of tumor cells with increased motility,
thereby enhancing its capability and probability of invad-
ing adjacent tissues and metastasis to remote organ sites
[32,33].
Conclusion
In summary, higher expression in MCM2 and gelsolin was
significantly associated with poorer prognosis in patients
with NSCLC, which suggests that higher tumor prolifera-
tion and motility may be important in the prognosis of
NSCLC. Ki-67 did not display apparent prognostic value
in NSCLC in our study sample. Composite application of
proliferation and motility markers may be more valuable
than use of a single marker in assessing tumor prognosis.
This combinatorial approach may also prove valuable in
assessing response to anticancer treatment and the subse-
quent clinical outcomes.
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Table 3: Cox Regression of Risk of Death in Association with MCM2, Ki-67, and Gelsolin in 128 Patients with NSCLC, RPCI, 1995–1999
Variables Crude RR (95%CI) P value Adjusted RR (95%CI)* P value
MCM2†
Low (n = 49) 1.00 1.00
High (n = 79) 1.51 (0.94–2.41) 0.09 1.36 (0.84–2.20) 0.22
Ki-67‡
Low (n = 28) 1.00 1.00
High (n = 100) 0.70 (0.27–1.86) 0.47 0.59 (0.22–1.61) 0.30
Gelsolin†
Low (n = 86) 1.00 1.00
High (n = 42) 1.89 (1.20–2.98) 0.006 1.89 (1.17–3.05) 0.01
Gelsolin and MCM2†
Both low (n = 37) 1.00 1.00
GSN low, MCM2 high (n = 49) 1.34 (0.74–2.42) 0.33 1.34 (0.73–2.45) 0.34
GSN high, MCM2 low (n = 12) 1.62 (0.70–3.73) 0.26 2.08 (0.87–4.98) 0.10
GSN high, MCM2 high (n = 30) 2.59 (1.39–4.80) 0.003 2.32 (1.21–4.45) 0.01
* Adjusted for age, stage, adjuvant chemotherapy, family history of lung cancer, and smoking history.
† Results from Cox Proportional Hazards Regression.
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